Cholera

1. Clinical Overview

Summary

Cholera is an acute, potentially life-threatening secretory diarrhoeal disease caused by ingestion of food or water contaminated with toxigenic strains of Vibrio cholerae, specifically serogroups O1 and O139. [1] The hallmark of cholera is profuse, watery diarrhoea caused by cholera toxin (CT), which triggers massive secretion of water and electrolytes into the intestinal lumen, leading to characteristic "rice-water" stools and potentially fatal dehydration within hours. [2]

Cholera remains a global public health threat, with an estimated 1.3 to 4.0 million cases and 21,000 to 143,000 deaths annually worldwide. [3] The disease is endemic in regions of South Asia, sub-Saharan Africa, and Haiti, typically affecting populations with inadequate water sanitation and limited access to healthcare. Cholera outbreaks frequently follow natural disasters, armed conflicts, and humanitarian emergencies where water infrastructure is compromised. [4]

The cornerstone of cholera management is rapid and aggressive fluid replacement with oral rehydration solution (ORS) or intravenous fluids. With appropriate rehydration therapy, case fatality rates can be reduced from approximately 50% in untreated severe cases to less than 1%. [5] Antibiotics, while not a substitute for fluids, reduce stool volume and duration of shedding by approximately 50%. [6] Prevention strategies include safe water provision, sanitation improvements, health education, and increasingly, oral cholera vaccines (OCV) for outbreak control and high-risk populations. [7]

Key Facts

• Causative Organism: Vibrio cholerae serogroups O1 (El Tor and Classical biotypes) and O139 (toxigenic strains)
• Transmission: Faecal-oral route via contaminated water or food; person-to-person transmission is rare
• Incubation Period: 12 hours to 5 days (median 2-3 days) [8]
• Infective Dose: 10³-10⁶ organisms (reduced in achlorhydric patients or those on proton pump inhibitors)
• Fluid Loss Rate: Up to 1 litre per hour in severe cases; cumulative loss can exceed 20 litres per day
• Classic Presentation: "Rice-water" stools—profuse, watery, grey-white with mucus flecks, fishy odour
• Critical Treatment: Rehydration with ORS or IV Ringer's lactate—fluids save lives, not antibiotics
• Untreated Mortality: 50-70% in severe cholera gravis
• Treated Mortality: less than 1% with appropriate fluid replacement [9]
• Notifiable Disease: Immediate notification required under International Health Regulations (2005)

Clinical Pearls

"Cholera Kills by Dehydration, Not Sepsis": Vibrio cholerae does not invade the intestinal mucosa or cause bacteraemia. Death results from hypovolaemic shock secondary to massive fluid loss, not from systemic infection. Replace fluids adequately and patients survive.

"Rice-Water Stool is Pathognomonic": The characteristic profuse, watery stool with flecks of mucus resembling rice grains in water is virtually diagnostic in endemic areas and during outbreaks. The fishy odour is due to amines produced by bacterial metabolism.

"ORS: The Greatest Public Health Innovation": WHO oral rehydration solution has saved over 50 million lives since its introduction in the 1970s. [10] The principle of glucose-sodium cotransport (SGLT1) bypasses the cholera toxin-mediated secretory defect and rescues intestinal absorption.

"Match Input to Output": In severe cholera, measure stool output using a cholera cot with a bucket and replace volume-for-volume with ORS or IV fluids. Inadequate replacement equals death.

"The Disease of Poverty and Disaster": Cholera thrives where clean water is absent. It is a sentinel marker of failed sanitation infrastructure and social inequality.

---

2. Epidemiology

Global Burden

Cholera remains endemic in over 50 countries and causes recurrent epidemics. The true global burden is likely underestimated due to underreporting and surveillance limitations. [3]

• Annual Cases: 1.3–4.0 million cases worldwide
• Annual Deaths: 21,000–143,000 deaths [3]
• Case Fatality Rate: less than 1% with treatment; 50-70% without treatment [9]
• Endemic Regions: South Asia (Bangladesh, India), sub-Saharan Africa (DRC, Nigeria, Somalia, Kenya), Haiti
• Seventh Pandemic: Began 1961 in Indonesia; caused by V. cholerae O1 El Tor biotype; still ongoing [1]

Historical Context

• 1817–1923: Six cholera pandemics originating from the Ganges Delta
• 1961–present: Seventh pandemic (El Tor biotype), spread globally from Indonesia
• 1992: V. cholerae O139 serogroup emerged in Bangladesh; caused limited epidemics but did not replace O1 [11]
• 2010: Massive outbreak in Haiti following earthquake; over 820,000 cases and 9,792 deaths; first cholera in Haiti in > 100 years [12]
• 2016–2021: Yemen experienced the largest cholera outbreak in modern history with over 2.5 million suspected cases [13]

Risk Factors for Acquisition

Serogroups and Biotypes

V. cholerae O1 (responsible for > 99% of cases)

• El Tor biotype: Current pandemic strain; produces more asymptomatic carriers; more environmentally resilient
• Classical biotype: Historical; caused earlier pandemics; now rare; higher case fatality

V. cholerae O139 (Bengal serogroup)

• Emerged in 1992 in Bangladesh and India
• Limited geographic spread; has not replaced O1
• Capsule polysaccharide production distinguishes it from O1

Non-O1/Non-O139 strains: Can cause sporadic gastroenteritis but not epidemic cholera

Asymptomatic Carriage

• Approximately 75% of infected individuals have minimal or no symptoms [16]
• Asymptomatic carriers can excrete bacteria for 7-14 days
• Plays important role in environmental contamination and transmission

---

3. Aetiology and Pathophysiology

Microbiology

Vibrio cholerae

• Gram-negative, comma-shaped, facultative anaerobic bacillus
• Motile with single polar flagellum (darting motility on dark-field microscopy)
• Oxidase-positive; produces yellow colonies on TCBS (thiosulfate-citrate-bile salts-sucrose) agar
• Halophilic (salt-tolerant); thrives in brackish water and estuaries
• Serogroups defined by O (somatic) antigen; > 200 serogroups identified
• Only O1 and O139 produce cholera toxin and cause epidemic cholera

Virulence Factors

1. Cholera toxin (CT): A-B subunit exotoxin; causes secretory diarrhoea
2. Toxin co-regulated pilus (TCP): Adherence factor; required for colonization
3. Accessory colonization factors: Enhance attachment to intestinal epithelium
4. Neuraminidase and mucinase: Facilitate penetration through mucus layer

Pathophysiological Mechanism

┌──────────────────────────────────────────────────────────────────┐
│   CHOLERA TOXIN MECHANISM: MOLECULAR PATHOPHYSIOLOGY              │
├──────────────────────────────────────────────────────────────────┤
│                                                                  │
│  STEP 1: Ingestion and Gastric Survival                          │
│  ─────────────────────────────                                   │
│  • Infective dose: 10³–10⁶ organisms (higher in normal gastric   │
│    pH; lower in achlorhydria or with food/antacids)              │
│  • Bacteria survive gastric acid; motility aids passage          │
│                                                                  │
│  STEP 2: Colonization of Small Intestine                         │
│  ──────────────────────────────────                              │
│  • V. cholerae colonizes duodenum and jejunum                    │
│  • Toxin co-regulated pilus (TCP) mediates adherence to          │
│    enterocyte surface                                            │
│  • Bacteria remain in lumen; NO mucosal invasion or bacteremia   │
│                                                                  │
│  STEP 3: Cholera Toxin (CT) Secretion and Binding                │
│  ───────────────────────────────────────────                     │
│  • CT is A-B₅ subunit exotoxin                                   │
│  • B pentamer binds to GM1 ganglioside receptor on enterocyte    │
│    apical membrane                                               │
│  • A subunit (A1-A2) is internalized via receptor-mediated       │
│    endocytosis                                                   │
│                                                                  │
│  STEP 4: Intracellular A Subunit Activation                      │
│  ─────────────────────────────────────                           │
│  • A1 subunit ADP-ribosylates Gsα protein (stimulatory G protein)│
│  • Gsα is permanently activated → constitutive activation of     │
│    adenylate cyclase                                             │
│  • Massive increase in intracellular cAMP                        │
│                                                                  │
│  STEP 5: CFTR Channel Activation                                 │
│  ──────────────────────────────                                  │
│  • Elevated cAMP activates protein kinase A (PKA)                │
│  • PKA phosphorylates CFTR (cystic fibrosis transmembrane        │
│    conductance regulator) chloride channel                       │
│  • CFTR opens → massive Cl⁻ secretion into intestinal lumen      │
│  • Na⁺ absorption is inhibited                                   │
│                                                                  │
│  STEP 6: Osmotic Water Loss                                      │
│  ────────────────────────                                        │
│  • Luminal accumulation of Cl⁻ and Na⁺ creates osmotic gradient │
│  • Water follows electrolytes into lumen (osmosis)               │
│  • K⁺ and HCO₃⁻ also lost in stool                              │
│                                                                  │
│  STEP 7: Massive Secretory Diarrhoea                             │
│  ──────────────────────────────────                              │
│  • Profuse, isotonic fluid loss (up to 1 L/hour; 20+ L/day)     │
│  • "Rice-water"
appearance: watery stool with mucus flecks       │
│  • Stool electrolyte composition approximates plasma (isotonic)  │
│  • NO blood, NO pus (non-inflammatory)                           │
│                                                                  │
│  STEP 8: Dehydration and Complications                           │
│  ────────────────────────────────                                │
│  • Isotonic dehydration → hypovolaemic shock                     │
│  • Hypokalaemia (K⁺ loss in stool) → weakness, arrhythmias      │
│  • Metabolic acidosis (HCO₃⁻ loss) → Kussmaul breathing         │
│  • Acute kidney injury (pre-renal azotaemia)                     │
│  • Death from circulatory collapse if untreated                  │
│                                                                  │
└──────────────────────────────────────────────────────────────────┘

Why Oral Rehydration Solution Works

Principle of Glucose-Sodium Cotransport

Despite cholera toxin-mediated secretion, the SGLT1 (sodium-glucose cotransporter 1) on the enterocyte apical membrane remains functionally intact. [17]

• SGLT1 mechanism: Couples transport of 1 glucose molecule with 2 Na⁺ ions from lumen into enterocyte
• Water follows sodium: Na⁺ absorption creates osmotic gradient; water is absorbed paracellularly
• Bypasses secretory defect: SGLT1-mediated absorption is independent of cAMP/CFTR pathway
• Result: Net fluid absorption despite ongoing CT-mediated secretion

WHO ORS Composition (reduced-osmolarity formula): [18]

• Sodium: 75 mmol/L
• Glucose: 75 mmol/L
• Potassium: 20 mmol/L
• Chloride: 65 mmol/L
• Citrate: 10 mmol/L
• Total osmolarity: 245 mOsm/L

Reduced-osmolarity ORS reduces stool output by 20% compared to standard ORS and decreases the need for IV fluids. [19]

Electrolyte Losses

Stool is approximately isotonic with plasma, leading to isotonic dehydration (proportionate loss of water and electrolytes).

---

4. Clinical Presentation

Spectrum of Disease

Not all V. cholerae infections cause severe disease. The clinical spectrum includes: [16]

• Asymptomatic infection: 75% of infections (mild or no symptoms; bacterial shedding 7-14 days)
• Mild diarrhoea: 20% (self-limiting watery diarrhoea without significant dehydration)
• Moderate-severe cholera: 5% (requires hospitalization and IV fluids)
• Cholera gravis: 1-2% (severe dehydration, shock, high mortality without treatment)

Clinical Features

Symptoms

Absence of fever and blood in stool are key distinguishing features from invasive bacterial enteritis (e.g., Shigella, Campylobacter).

Signs of Dehydration (WHO Classification)

The WHO assessment of dehydration severity guides treatment decisions: [20]

Signs of Severe Dehydration and Shock

• Vital signs: Tachycardia, hypotension (systolic BP less than 90 mmHg), weak/absent radial pulse
• Skin: Cold, clammy extremities; reduced capillary refill time (> 3 seconds)
• Eyes: Deeply sunken eyes
• Breathing: Rapid, deep (Kussmaul breathing) indicating metabolic acidosis
• Consciousness: Altered mental status, confusion, lethargy, coma
• Urine output: Oliguria or anuria
• Peripheral cyanosis: Indicates severe shock

Paediatric Considerations

Children are at higher risk of severe dehydration and complications:

• Rapid progression: Smaller fluid reserves; dehydration develops faster
• Hypoglycaemia: More common in young children; can cause seizures and altered consciousness
• Depressed fontanelle: In infants; indicates severe dehydration
• Irritability or lethargy: Early signs of dehydration in children
• High case fatality: Without prompt treatment

---

5. Differential Diagnosis

Key Differentials of Acute Watery Diarrhoea

Clinical Clues to Cholera:

• Endemic area or recent outbreak
• Profuse "rice-water" stools without blood or mucus
• Rapid onset severe dehydration
• Afebrile or low-grade fever
• Painless diarrhoea

---

6. Investigations

Clinical Diagnosis

In endemic areas or during outbreaks, cholera is primarily a clinical diagnosis based on:

• Acute watery diarrhoea (profuse, rice-water stools)
• Severe dehydration
• Epidemiological context (outbreak, endemic area, travel history)

Empirical treatment with rehydration should never be delayed pending laboratory confirmation.

Laboratory Confirmation

Microbiological Diagnosis

Specimen collection:

• Acute stool or rectal swab collected before antibiotics (if possible)
• Transport medium: Cary-Blair or Venkatraman-Ramakrishna (VR) medium
• Transport rapidly to lab; V. cholerae is fragile

Supportive Laboratory Tests

Red flag laboratory findings:

• K⁺ less than 2.5 mmol/L: Risk of arrhythmias; urgent potassium replacement needed
• pH less than 7.2: Severe metabolic acidosis; aggressive IV rehydration required
• Creatinine > 300 μmol/L: Acute kidney injury; may need dialysis if not improving with fluids
• Glucose less than 3.0 mmol/L: Hypoglycaemia; IV dextrose needed (especially children)

Public Health Investigations

• Strain characterization: Serotyping, biotyping, antimicrobial resistance testing
• Outbreak investigation: Water source testing, epidemiological surveillance
• Contact tracing: Identify secondary cases; household/community screening
• Notification: Immediate reporting to public health authorities under IHR (2005)

---

7. Management

Principles of Cholera Management

Key Principle: Cholera is treated with fluids, not antibiotics. Rehydration is the cornerstone of therapy; antibiotics are adjunctive.

1. Rapid assessment of dehydration severity (WHO classification)
2. Immediate rehydration (ORS or IV fluids)
3. Match output to input (replace ongoing losses)
4. Antibiotics to reduce duration and transmission (adjunctive, not primary)
5. Zinc supplementation in children
6. Monitoring and reassessment

Rehydration Therapy: WHO Treatment Plans

The WHO recommends three treatment plans based on dehydration severity: [20]

┌─────────────────────────────────────────────────────────────────────┐
│   CHOLERA TREATMENT ALGORITHM: REHYDRATION FIRST                    │
├─────────────────────────────────────────────────────────────────────┤
│                                                                     │
│  ASSESS DEHYDRATION (Look, Feel, Ask)                               │
│  ──────────────────────────────────────                             │
│  • Mental status, eyes, mouth, thirst, skin pinch, pulse            │
│  • Classify: None/Mild | Moderate (Some) | Severe                   │
│                                                                     │
│  ═══════════════════════════════════════════════════════════════    │
│                                                                     │
│  PLAN A: NO OR MILD DEHYDRATION (less than 5% body weight loss)              │
│  ─────────────────────────────────────────────────                  │
│  • Manage at home with ORS                                          │
│  • ORS: 10 ml/kg after each loose stool (adults: 200-400 ml)       │
│  • Continue normal feeding (breastfeeding if infant)                │
│  • Return if: unable to drink, worsening diarrhoea, fever, blood    │
│                                                                     │
│  ═══════════════════════════════════════════════════════════════    │
│                                                                     │
│  PLAN B: MODERATE DEHYDRATION (5-10% body weight loss)              │
│  ──────────────────────────────────────────────────                 │
│  • ORS 75 ml/kg over 4 hours (under supervision)                    │
│  • Reassess every 1-2 hours                                         │
│  • Continue ORS 10 ml/kg after each stool                           │
│  • If unable to drink or vomiting repeatedly → IV fluids (Plan C)   │
│  • If improving → discharge with Plan A instructions                │
│                                                                     │
│  Example (adult 60 kg): 75 ml/kg × 60 kg = 4,500 ml ORS over 4h     │
│  (approx. 1,125 ml/hour)                                            │
│                                                                     │
│  ═══════════════════════════════════════════════════════════════    │
│                                                                     │
│  PLAN C: SEVERE DEHYDRATION (> 10% body weight loss) OR SHOCK        │
│  ──────────────────────────────────────────────────────             │
│  IMMEDIATE IV FLUID RESUSCITATION (Ringer's Lactate preferred)      │
│                                                                     │
│  Adults and children > 1 year:                                       │
│  • First bolus: 30 ml/kg over 30 minutes (STAT)                     │
│  • Then: 70 ml/kg over 2.5 hours                                    │
│  • Total: 100 ml/kg IV fluids over 3 hours                          │
│                                                                     │
│  Infants less than 1 year:                                                   │
│  • First: 30 ml/kg over 1 hour                                      │
│  • Then: 70 ml/kg over 5 hours                                      │
│                                                                     │
│  Example (adult 60 kg):                                             │
│  • 30 ml/kg × 60 kg = 1,800 ml over 30 min (3.6 L/hour rate)        │
│  • Then 70 ml/kg × 60 kg = 4,200 ml over 2.5 hours                  │
│                                                                     │
│  REASSESS EVERY 15-30 MINUTES:                                      │
│  • If radial pulse still weak, increase rate                        │
│  • Once stable and able to drink → switch to ORS                    │
│                                                                     │
│  ONGOING LOSSES:                                                    │
│  • Measure stool output (cholera cot with bucket)                   │
│  • Replace volume-for-volume with ORS or IV fluids                  │
│                                                                     │
└─────────────────────────────────────────────────────────────────────┘

Choice of IV Fluid

Ringer's Lactate (Hartmann's solution) is the preferred IV fluid: [21]

• Contains Na⁺, K⁺, Cl⁻, lactate (converted to bicarbonate)
• Closest to cholera stool electrolyte composition
• Corrects acidosis (lactate → HCO₃⁻)

0.9% Normal Saline is an acceptable alternative if Ringer's lactate unavailable

• May worsen metabolic acidosis (hyperchloremic acidosis)
• Does not contain potassium (supplement separately)

Avoid:

• Dextrose solutions alone (no electrolytes; inadequate resuscitation)
• Hypotonic fluids (risk of hyponatraemia)

Oral Rehydration Solution (ORS)

WHO Reduced-Osmolarity ORS (WHO-ORS): [18]

Preparation:

• Standard WHO ORS sachet dissolved in 1 litre of clean water

If commercial ORS unavailable (emergency home recipe):

• 6 level teaspoons of sugar + ½ level teaspoon of salt in 1 litre clean water
• Not ideal (lacks potassium and citrate) but life-saving

Rice-based ORS (effective but less practical):

• Rice powder replaces glucose; slower absorption, longer-lasting effect
• 50-80 g rice powder + electrolytes in 1 L water

Antibiotic Therapy

Antibiotics are adjunctive, not primary therapy. They reduce: [6]

• Stool volume by ~50%
• Duration of diarrhoea by ~50%
• Duration of V. cholerae excretion (reduces transmission)
• Need for IV fluids and hospital stay

Indications:

• Severe dehydration
• Confirmed or suspected cholera (during outbreaks)

First-Line Antibiotics (single-dose therapy preferred):

Antimicrobial Resistance: Increasing resistance to fluoroquinolones and azithromycin reported in some regions. [22] Local susceptibility patterns should guide therapy.

Zinc Supplementation (Children)

Indication: All children less than 5 years with acute diarrhoea (including cholera) [23]

Dose:

• Children less than 6 months: 10 mg daily × 10-14 days
• Children ≥6 months: 20 mg daily × 10-14 days

Benefits:

• Reduces duration of diarrhoea by 25%
• Reduces stool volume
• Prevents recurrent diarrhoea episodes in following 2-3 months

Formulation: Zinc sulfate or zinc acetate dispersible tablets

Monitoring and Supportive Care

Monitoring parameters:

• Vital signs: HR, BP, RR every 15-30 min (severe cases); then hourly
• Urine output: Aim for > 0.5 ml/kg/hour (adults); > 1 ml/kg/hour (children)
• Stool output: Measure volume (cholera cot); replace volume-for-volume
• Mental status: Alert, oriented
• Electrolytes: K⁺, creatinine, glucose (especially if altered consciousness or not improving)
• Weight: Daily weight to assess hydration

Supportive care:

• Nutrition: Continue feeding as soon as able to eat; breastfeeding in infants; normal diet; avoid prolonged fasting
• Glucose monitoring: Especially in children (risk of hypoglycaemia)
• Hygiene: Handwashing, safe stool disposal, isolation/cohorting

Potassium replacement:

• ORS contains potassium (20 mmol/L)
• If severe hypokalaemia (K⁺ less than 2.5 mmol/L): IV potassium chloride 20-40 mmol in 1 L IV fluid over hours (NOT bolus)

Bicarbonate replacement:

• Usually corrects with Ringer's lactate or ORS
• Severe acidosis (pH less than 7.1): consider sodium bicarbonate 50-100 mmol IV (caution: risk of volume overload)

Special Populations

Pregnancy

• Rehydration: Same principles apply; aggressive IV fluids if severe
• Antibiotics: Azithromycin preferred (safe in pregnancy); avoid tetracyclines and fluoroquinolones

Children and Infants

• Higher risk: Rapid progression, hypoglycaemia, seizures
• Antibiotics: Azithromycin preferred
• Zinc supplementation: Mandatory
• Breastfeeding: Continue throughout illness

Elderly and Comorbidities

• Careful fluid balance: Risk of fluid overload (heart failure, renal impairment)
• Monitor closely: More vulnerable to shock and complications

---

8. Complications

Complications of Severe Dehydration

Pregnancy-Specific Complications

• Miscarriage and preterm labour: Dehydration and shock increase risk
• Fetal distress: Maternal hypovolaemia reduces placental perfusion
• Management: Aggressive rehydration; azithromycin; close fetal monitoring

Multi-Organ Failure

In untreated severe cases:

• Shock → multi-organ hypoperfusion
• AKI, liver dysfunction, cardiac arrhythmias
• Mortality > 50% without treatment

---

9. Prognosis and Outcomes

Mortality

Key prognostic message: Cholera is highly lethal without treatment but has excellent prognosis with simple fluid replacement. [9]

Recovery

• Duration of illness: 3-6 days with treatment
• Complete recovery: Expected in most cases; no long-term sequelae
• Return to normal activity: Within 1 week
• Bacterial shedding: Ceases within 1-2 weeks (antibiotics shorten duration)

Factors Associated with Poor Prognosis

• Delayed presentation: Shock on arrival
• Extremes of age: Very young children, elderly
• Comorbidities: Malnutrition, HIV, chronic disease
• Severe hypokalaemia or acidosis: Not corrected promptly
• Inadequate fluid replacement: Insufficient volume or delayed treatment

Immunity

• Post-infection immunity: 3-5 years of protection against same serogroup [24]
• Cross-protection: Limited between O1 and O139
• Reinfection: Possible after immunity wanes or with different serogroup

---

10. Prevention and Control

Primary Prevention: Water, Sanitation, and Hygiene (WASH)

Long-term cholera control requires safe water, sanitation, and hygiene: [25]

• Safe water supply: Chlorination, boiling, filtration; protected wells
• Sanitation: Toilets, safe disposal of faeces; eliminate open defecation
• Hygiene: Handwashing with soap; safe food handling
• Environmental management: Proper sewage disposal; water treatment infrastructure

Oral Cholera Vaccines (OCV)

Oral cholera vaccines are an important adjunct to WASH interventions, particularly for outbreak control and high-risk populations. [7]

Available Vaccines:

Indications for OCV:

• Outbreak response: Mass vaccination campaigns in affected areas
• Endemic areas: Routine vaccination in high-risk communities
• Humanitarian emergencies: Refugee camps, displaced populations, post-disaster
• Travellers: High-risk travellers (healthcare/aid workers in endemic areas); Dukoral licensed for travellers

WHO Recommendations: [7]

• OCVs should be used alongside, not instead of, WASH interventions
• Prequalified vaccines (Shanchol/Euvichol) suitable for mass campaigns
• Single-dose regimen provides ~50% protection (considered in outbreak settings when supply limited)

Efficacy Data:

• Single dose: 40-50% protection for 6 months [26]
• Two doses: 60-65% protection for 3-5 years; higher in first 2 years [7]
• Herd immunity: Mass vaccination (> 50% coverage) reduces transmission in community

Outbreak Response

During a cholera outbreak, rapid response is critical: [4]

1. Case management: Establish Cholera Treatment Centers (CTCs); aggressive rehydration
2. Surveillance: Active case finding; rapid diagnostic testing; reporting
3. Water and sanitation: Chlorinate water supplies; latrine construction; hygiene promotion
4. Oral cholera vaccination: Reactive mass vaccination in affected areas
5. Community engagement: Health education; safe water and food messages
6. Epidemiological investigation: Identify source; environmental testing

Traveller Precautions

For travellers to endemic areas:

• "Boil it, cook it, peel it, or forget it": Avoid raw/undercooked food, raw vegetables, ice, tap water
• Drink only bottled or boiled water
• Avoid street food and shellfish
• Handwashing with soap before eating
• Oral cholera vaccine (Dukoral) for high-risk travellers (consider for healthcare/aid workers, not routine tourists)

Chemoprophylaxis

Not recommended for contacts or travellers due to:

• Short duration of protection
• Promotes antimicrobial resistance
• No evidence of benefit compared to hygiene measures

---

11. Public Health and Notification

International Health Regulations (IHR 2005)

Cholera is a disease of international concern under IHR (2005). Countries must: [27]

• Notify WHO of all cholera cases (immediate notification)
• Report outbreaks within 24 hours
• Implement control measures to prevent international spread
• Avoid unnecessary trade/travel restrictions

Case Definitions (WHO):

• Suspected case: Acute watery diarrhoea in a person > 5 years in area with cholera outbreak
• Confirmed case: V. cholerae O1 or O139 isolated from stool in any person with diarrhoea

Contact Tracing and Management

• Household contacts: Education on hygiene, ORS availability; monitor for symptoms
• Antibiotic prophylaxis: NOT recommended (ineffective, promotes resistance)
• Quarantine: Not indicated (low risk of person-to-person transmission)

Cholera as a Marker of Inequality

Cholera is a disease of poverty and social inequality. Its presence indicates:

• Lack of clean water and sanitation infrastructure
• Displacement, conflict, or humanitarian crisis
• Systemic failures in public health and governance

Long-term solution: Sustainable development, universal access to safe water and sanitation (UN Sustainable Development Goal 6).

---

12. Exam-Focused Sections

Common Viva Questions

Q1: "Tell me about cholera."

Model Answer: "Cholera is an acute secretory diarrhoeal illness caused by toxigenic Vibrio cholerae, specifically serogroups O1 and O139. It is transmitted via the faecal-oral route, primarily through contaminated water. The hallmark is profuse watery 'rice-water' diarrhoea leading to severe dehydration and potentially fatal hypovolaemic shock within hours.

The pathophysiology involves cholera toxin, an A-B subunit exotoxin, which ADP-ribosylates Gs protein, leading to persistent activation of adenylate cyclase, increased intracellular cAMP, and opening of CFTR chloride channels. This results in massive chloride and water secretion into the intestinal lumen.

The cornerstone of treatment is rapid rehydration with oral rehydration solution or intravenous Ringer's lactate. ORS works via the glucose-sodium cotransporter SGLT1, which remains intact despite cholera toxin activity. Antibiotics such as doxycycline or azithromycin reduce stool volume and duration by 50% but are adjunctive to fluids. With appropriate rehydration, mortality is less than 1%; without treatment, it approaches 50-70%."

Q2: "How does oral rehydration solution work in cholera?"

Model Answer: "Oral rehydration solution exploits the glucose-sodium cotransporter, SGLT1, on the apical membrane of enterocytes. This transporter couples the uptake of one glucose molecule with two sodium ions from the intestinal lumen into the enterocyte. Water follows sodium absorption osmotically via paracellular pathways.

Crucially, SGLT1-mediated absorption is independent of the cAMP-CFTR pathway that is activated by cholera toxin. Therefore, even though cholera toxin causes massive chloride and water secretion, glucose-coupled sodium absorption remains functional and drives net fluid absorption, effectively bypassing the secretory defect.

WHO reduced-osmolarity ORS contains 75 mmol/L sodium and 75 mmol/L glucose, optimized for maximal absorption while avoiding osmotic diarrhoea. Studies have shown it reduces stool output by 20% compared to standard ORS and decreases the need for intravenous fluids."

Q3: "What are the indications for oral cholera vaccine?"

Model Answer: "Oral cholera vaccines are used as an adjunct to water, sanitation, and hygiene interventions. The main indications are:

First, reactive mass vaccination during outbreaks to control spread in affected communities. Second, preemptive vaccination in endemic areas and high-risk populations such as refugee camps or areas with poor sanitation. Third, vaccination of travelers at high risk, such as healthcare or humanitarian workers deploying to endemic zones, though routine tourists generally do not require vaccination.

The two main vaccines are Dukoral, a killed whole-cell vaccine with recombinant B subunit requiring two doses, and Shanchol or Euvichol, bivalent killed whole-cell vaccines also requiring two doses given 2 weeks apart. Two-dose efficacy is approximately 60-85% for 3-5 years, though protection wanes over time. A single dose provides about 40-50% protection for 6 months, which is sometimes used in outbreak settings when supply is limited.

Importantly, vaccination does not replace safe water and sanitation, which are the definitive long-term solutions."

High-Yield Exam Facts

• Cholera toxin mechanism: ADP-ribosylation of Gs protein → ↑ cAMP → CFTR activation → Cl⁻ secretion
• Rice-water stools: Pathognomonic; watery, grey-white with mucus flecks
• Isotonic dehydration: Stool electrolyte composition similar to plasma
• ORS mechanism: Glucose-sodium cotransport via SGLT1 (bypasses cAMP pathway)
• First-line antibiotic (adult): Doxycycline 300 mg single dose
• First-line antibiotic (child/pregnancy): Azithromycin 1 g (20 mg/kg) single dose
• Zinc supplementation: 20 mg daily × 10-14 days in children less than 5 years
• Mortality: 50-70% untreated; less than 1% with appropriate fluids
• IV fluid of choice: Ringer's lactate (Hartmann's)
• WHO Plan C (severe dehydration): 100 ml/kg over 3 hours (30 ml/kg in 30 min, then 70 ml/kg over 2.5h)
• Blood group O: 2-fold increased risk of severe disease
• Notifiable disease: Immediate notification under IHR (2005)

Common Mistakes to Avoid

❌ Relying on antibiotics instead of fluids: Fluids save lives; antibiotics are adjunctive.

❌ Using hypotonic IV fluids (e.g., 0.45% saline or dextrose alone): Causes hyponatraemia; use Ringer's lactate or normal saline.

❌ Delaying rehydration for laboratory confirmation: Treat empirically based on clinical presentation; do not wait for stool culture.

❌ Forgetting potassium and zinc: Hypokalaemia is common; zinc reduces duration in children.

❌ Inadequate volume replacement: Must replace ongoing stool losses volume-for-volume.

❌ Missing hypoglycaemia in children: Check glucose in children with altered consciousness.

---

13. Patient and Layperson Explanation

What is Cholera?

Cholera is a serious infection of the gut caused by a bacterium called Vibrio cholerae. It spreads through contaminated water or food, usually in areas where sanitation is poor. The infection causes severe watery diarrhoea that can lead to dangerous dehydration within hours if not treated.

How Do You Catch Cholera?

• Drinking water contaminated with the cholera bacteria
• Eating food washed in unsafe water or prepared by someone with contaminated hands
• Eating raw or undercooked shellfish from contaminated waters

Cholera is common in parts of Africa, Asia, and Haiti where clean water is scarce. It is very rare in developed countries with modern sanitation.

What Are the Symptoms?

• Sudden, severe watery diarrhoea (often described as "rice water" because of its appearance)
• Vomiting
• Muscle cramps
• Feeling very weak and dizzy due to fluid loss
• Dry mouth and extreme thirst
• Little or no urination

Important: Cholera can cause life-threatening dehydration very quickly—sometimes within hours—so urgent medical care is needed.

How is Cholera Treated?

The most important treatment is replacing lost fluids:

• Oral rehydration solution (ORS): A special drink containing salts and sugar that helps your body absorb water. It is highly effective and has saved millions of lives.
• Intravenous fluids: Given through a drip if dehydration is severe.
• Antibiotics: May be given to shorten the illness and reduce the amount of diarrhoea, but fluids are the main treatment.
• Zinc supplements: Given to children to help recovery.

With prompt treatment, nearly everyone recovers fully within a few days. Without treatment, cholera can be fatal.

How Can You Prevent Cholera?

When traveling to areas where cholera is common:

• Only drink safe water: Bottled water, boiled water, or water treated with purification tablets
• Avoid ice in drinks unless you know it is made from safe water
• Eat only thoroughly cooked food served hot
• Peel fruits and vegetables yourself
• Avoid raw shellfish and street food
• Wash your hands frequently with soap, especially before eating

A cholera vaccine is available and may be recommended for travelers going to high-risk areas, particularly healthcare or aid workers.

---

14. References

1. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832. doi:10.1371/journal.pntd.0003832

2. Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. Cholera. Lancet. 2017;390(10101):1539-1549. doi:10.1016/S0140-6736(17)30559-7

3. Davis WW, Narra R, Mintz ED. Cholera. Curr Epidemiol Rep. 2018;5(3):303-315. doi:10.1007/s40471-018-0162-z

4. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet. 2004;363(9404):223-233. doi:10.1016/S0140-6736(03)15328-7

5. Mahalanabis D, Choudhuri AB, Bagchi NG, et al. Oral fluid therapy of cholera among Bangladesh refugees. Johns Hopkins Med J. 1973;132(4):197-205. PMID:4574424

6. Leibovici-Weissman Y, Neuberger A, Bitterman R, et al. Antimicrobial drugs for treating cholera. Cochrane Database Syst Rev. 2014;(6):CD008625. doi:10.1002/14651858.CD008625.pub2

7. Bi Q, Ferreras E, Pezzoli L, et al. Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(10):1080-1088. doi:10.1016/S1473-3099(17)30359-6

8. Kaper JB, Morris JG Jr, Levine MM. Cholera. Clin Microbiol Rev. 1995;8(48):48-86. doi:10.1128/CMR.8.1.48

9. Nelson EJ, Harris JB, Morris JG Jr, Calderwood SB, Camilli A. Cholera transmission: the host, pathogen and bacteriophage dynamics. Nat Rev Microbiol. 2009;7(10):693-702. doi:10.1038/nrmicro2204

10. Fontaine O, Garner P, Bhan MK. Oral rehydration therapy: the simple solution for saving lives. BMJ. 2007;334(Suppl 1):s14. doi:10.1136/bmj.39044.653348.94

11. Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae. Microbiol Mol Biol Rev. 1998;62(4):1301-1314. doi:10.1128/MMBR.62.4.1301-1314.1998

12. Barzilay EJ, Schaad N, Magloire R, et al. Cholera surveillance during the Haiti epidemic—the first 2 years. N Engl J Med. 2013;368(7):599-609. doi:10.1056/NEJMoa1204927

13. Camacho A, Bouhenia M, Alyusfi R, et al. Cholera epidemic in Yemen, 2016-18: an analysis of surveillance data. Lancet Glob Health. 2018;6(6):e680-e690. doi:10.1016/S2214-109X(18)30230-4

14. Clemens JD, Sack DA, Harris JR, et al. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis. 1989;159(4):770-773. doi:10.1093/infdis/159.4.770

15. Harris JB, Khan AI, LaRocque RC, et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun. 2005;73(11):7422-7427. doi:10.1128/IAI.73.11.7422-7427.2005

16. Ryan ET, Calderwood SB. Cholera vaccines. Clin Infect Dis. 2000;31(2):561-565. doi:10.1086/313951

17. Field M, Rao MC, Chang EB. Intestinal electrolyte transport and diarrheal disease (part 1). N Engl J Med. 1989;321(12):800-806. doi:10.1056/NEJM198909213211206

18. World Health Organization. The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers. 4th rev. WHO; 2005.

19. CHOICE Study Group. Multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of a reduced osmolarity oral rehydration salts solution in children with acute watery diarrhea. Pediatrics. 2001;107(4):613-618. doi:10.1542/peds.107.4.613

20. World Health Organization and UNICEF. Clinical Management of Acute Diarrhoea. WHO/UNICEF Joint Statement. WHO; 2004.

21. Alam NH, Ashraf H, Khan WA, Karim MM, Fuchs GJ. Efficacy of short-course azithromycin in cholera. J Antimicrob Chemother. 2003;51(5):1245-1247. doi:10.1093/jac/dkg193

22. Dutta D, Kaushik A, Kumar D, Bag S. Foodborne Pathogenic Vibrios: Antimicrobial Resistance. Front Microbiol. 2021;12:638331. doi:10.3389/fmicb.2021.638331

23. Lazzerini M, Wanzira H. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2016;12(12):CD005436. doi:10.1002/14651858.CD005436.pub5

24. Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev. 1983;47(4):510-550. doi:10.1128/mr.47.4.510-550.1983

25. World Health Organization. Cholera Vaccines: WHO Position Paper – August 2017. Weekly Epidemiological Record. 2017;92(34):477-500.

26. Qadri F, Wierzba TF, Ali M, et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med. 2016;374(18):1723-1732. doi:10.1056/NEJMoa1510330

27. World Health Organization. International Health Regulations (2005). 3rd ed. WHO; 2016.

---